Skip to main content

Radiation Oncology Perspective

The Radiation Oncology Perspective: Genomic vs Genetic Testing in Prostate Cancer



A Frontline Forum hosted by CancerNetwork during the 2025 American College of Radiation Oncology Summit in March focused on gene expression testing options for patients with prostate cancer.

The discussion centered on genetic vs genomic testing, current NCCN guidelines, and decisions based on which testing options to use. Following the program, CancerNetwork spoke with leading clinicians in the radiation oncology space regarding the use of these tests, androgen deprivation therapy (ADT), and the thought process for selecting patients for active surveillance.

To begin, the distinction between a genomic biomarker vs germline testing was mentioned. A genomic biomarker includes a measurable DNA or RNA characteristic that can be used to indicate normal biological processes, disease, or response to treatment. Germline testing is the analysis of DNA to identify genetic variations that may be associated with health risks or cancer predisposition.

Decipher Prostate has a level 1B evidence rating among the NCCN guidelines. A news release from the developer stated that Decipher received the rating because of evidence from the postbiopsy and postprostatectomy settings.

Decipher Prostate is a 22-gene test incorporating RNA whole-transcriptome analysis plus machine learning to help inform treatment decisions for patients with prostate cancer. Biopsy or surgically resected samples are used to provide a patient’s risk for developing metastases with standard treatment. This information will better personalize care as well as provide options that are less treatment-intensive. Validation for this test comes from more than 75 studies and more than 100,000 patients.

The Oncotype DX test is a 17-gene assay that was created to assess 12 cancer-related genes and 5 reference genes through biopsy tissue.

A recent study looking into genomic classifiers across 10 studies reported the risk reclassification. In studies that had a low risk of bias and patients with prostate cancer who were very low or low risk, patients were more likely to have their risk levels classified as the same or lower with Oncotype DX at 100% to 88.1%, Decipher at 87.2% to 82.9%, and Prolaris at 76.9%. There was, however, 1 randomized trial of genomic classifiers with Oncotype DX that reclassified 34.5% of patients who were very low risk and 29.4% who were low risk to the high-risk category.

The study takeaway mentioned a need for more trials to better determine the role of genomic classifiers for patients with newly diagnosed prostate cancer who are considering first-line treatment.

The NCCN guidelines include Prolaris in the prostate cancer guidelines with category level 2A of evidence. This is a molecular diagnostic test that can provide personalized information regarding the aggressiveness of a tumor and can determine whether a patient should pursue treatment. Of note, a news release from Myriad Genetics stated that it is the only biomarker test to quantify the benefits of ADT to radiation therapy.

Findings from a study by Tward et al found the combined clinical cell-cycle risk (CCR) score for a single therapy that is a continuous variable was able to prognosticate metastases (HR, 3.97; 95% CI, 2.61-6.06) as well as for the dichotomized threshold (HR, 15.90; 95% CI, 5.43-46.52).5 If patients were given single-modality therapy of radiation therapy or surgery, the 10-year Kaplan Meier score was 4.3% (95% CI, 1.0%-17.1%) for those with a CCR score below the threshold and 20.4% (95% CI, 13.2%-30.7%) for those with a score above the threshold.

The authors stated that if the CCR score was below the 2.112 multimodality threshold, patients could safely avoid multimodality therapy. Additionally, clinicians can use the CCR scores to counsel patients on which type of therapy would be most effective for intermediate or high-risk prostate cancer.

A discussion during the program also occurred around clinical decision-making. The program also focused on active surveillance, which is used to identify appropriate candidates who are eligible for this treatment with favorable or intermediate disease; treatment modality selection included guiding choices between single and multimodality approaches; and ADT optimization was determining if there was a benefit by adding ADT to radiation therapy.

breast cancer, lung cancer, prostate cancer, colorectal cancer, pancreatic cancer, leukemia, lymphoma, melanoma, ovarian cancer, cervical cancer, esophageal cancer, kidney cancer, liver cancer, thyroid cancer, bladder cancer, bone cancer, stomach cancer, multiple myeloma, brain tumor, and skin cancer

#BreastCancer, #LungCancer, #ProstateCancer, #ColorectalCancer, #PancreaticCancer, #Leukemia, #Lymphoma, #Melanoma, #OvarianCancer, #CervicalCancer, #EsophagealCancer, #KidneyCancer, #LiverCancer, #ThyroidCancer, #BladderCancer, #BoneCancer, #StomachCancer, #MultipleMyeloma, #BrainTumor, #SkinCancer

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more